anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Potassium Acetate Injection, USP (2 mEq/mL) must be diluted before use.

To avoid potassium intoxication, infuse potassium-containing solutions slowly. Potassium replacement therapy should be monitored whenever possible by continuous or serial electrocardiography (ECG). Serum potassium levels are not necessarily dependable indicators of tissue potassium levels.

Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present.

In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention.

Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.

WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
Metabolic dysfunction-associated steatohepatitis (MASH) - previously described as nonalcoholic steatohepatitis (NASH) - is a major driver of liver fibrosis in humans, while liver fibrosis is a key determinant of all-cause mortality in liver disease independent of MASH occurrence. CCAAT/enhancer binding protein α (CEBPA), as a versatile ligand-independent transcriptional factor, has an important function in myeloid cells, and is under clinical evaluation for cancer therapy. CEBPA is also expressed in hepatocytes and regulates glucolipid homeostasis; however, the role of hepatocyte-specific CEBPA in modulating liver fibrosis progression is largely unknown. Here, hepatic CEBPA expression was found to be decreased during MASH progression both in humans and mice, and hepatic CEBPA mRNA was negatively correlated with MASH fibrosis in the human liver. CebpaΔHep mice had markedly enhanced liver fibrosis induced by a high-fat, high-cholesterol, high-fructose diet or carbon tetrachloride. Temporal and spatial hepatocyte-specific CEBPA loss at the progressive stage of MASH in CebpaΔHep,ERT2 mice functionally promoted liver fibrosis. Mechanistically, hepatocyte CEBPA directly repressed Spp1 transactivation to reduce the secretion of osteopontin, a fibrogenesis inducer of hepatic stellate cells. Forced hepatocyte-specific CEBPA expression reduced MASH-associated liver fibrosis. These results demonstrate an important role for hepatocyte-specific CEBPA in liver fibrosis progression, and may help guide the therapeutic discoveries targeting hepatocyte CEBPA for the treatment of liver fibrosis.
The booklet-delivered self-help CBT includes six weekly sessions (i.e., participants are anticipated to access the intervention every day for 42 days) that are related to psychoeducation of depression, cognitive behavioural techniques( e.g. behavioral activation, cognitive restructuring), stress management, mindfulness, goal-setting, and/or positive psychology.
A method for analyzing an electrocardiography (ECG) signal is provided. The ECG signal is measured through a sensor. One or more specified waveforms in the ECG signal are detected. Multiple ECG features from each specified waveform are captured. The ECG features are input into a plurality of candidate models to obtain a plurality of candidate scores. Each candidate score is compared with a standard value to obtain an ideal score among the candidate scores. One candidate model corresponding to the ideal score is selected as a risk prediction model to predict disease risk through the risk prediction model.
Allogeneic and autologous bone marrow transplantation is currently the only curative option for many patients with life-threatening hematologic illnesses and malignancies. Peripheral blood stem cell (PBSC) infusion has been associated with systemic toxicities including arrhythmias, hypertension, and organ dysfunction. It has been thought that the preservative dimethyl sulfoxide (DMSO) that is frequently used to store frozen PBSCs may be the etiology of the adverse effects that occur during the infusion. However, we hypothesize that the red blood cells that rupture upon thawing infused with the graft release free hemoglobin which scavenges nitric oxide. This can lead to systemic vasoconstriction and organ dysfunction. In this protocol, we will monitor subjects who are undergoing PBSC transplantation with either fresh grafts that lack DMSO or frozen whole grafts. We will also evaluate patients who receive purified stem cell grafts, which will contain negligible red blood cells and associated free hemoglobin. We will then measure the frequency of infusion-related systemic toxicity and organ dysfunction between the groups.
The initial oral dose of Cyclosporine Capsules USP MODIFIED can be given 4 to 12 hours prior to transplantation or be given postoperatively. The initial dose of Cyclosporine Capsules USP MODIFIED varies depending on the transplanted organ and the other immunosuppressive agents included in the immunosuppressive protocol. In newly transplanted patients, the initial oral dose of Cyclosporine Capsules USP MODIFIED is the same as the initial oral dose of Sandimmune® (Cyclosporine Capsules USP). Suggested initial doses are available from the results of a 1994 survey of the use of Sandimmune® (Cyclosporine Capsules USP) in US transplant centers. The mean ±SD initial doses were 9±3 mg/kg/day for renal transplant patients (75 centers), 8±4 mg/kg/day for liver transplant patients (30 centers), and 7±3 mg/kg/day for heart transplant patients (24 centers). Total daily doses were divided into two equal daily doses. The Cyclosporine Capsules USP MODIFIED dose is subsequently adjusted to achieve a pre-defined cyclosporine blood concentration (see Blood Concentration Monitoring in Transplant Patients, below). If cyclosporine trough blood concentrations are used, the target range is the same for Cyclosporine Capsules USP MODIFIED as for Sandimmune® (Cyclosporine Capsules USP). Using the same trough concentration target range for Cyclosporine Capsules USP MODIFIED as for Sandimmune® (Cyclosporine Capsules USP) results in greater cyclosporine exposure when Cyclosporine Capsules USP MODIFIED is administered (see Pharmacokinetics, Absorption). Dosing should be titrated based on clinical assessments of rejection and tolerability. Lower Cyclosporine Capsules USP MODIFIED doses may be sufficient as maintenance therapy.

Adjunct therapy with adrenal corticosteroids is recommended initially. Different tapering dosage schedules of prednisone appear to achieve similar results. A representative dosage schedule based on the patient’s weight started with 2 mg/kg/day for the first 4 days tapered to 1 mg/kg/day by 1 week, 0.6 mg/kg/day by 2 weeks, 0.3 mg/kg/day by 1 month, and 0.15 mg/kg/day by 2 months and thereafter as a maintenance dose. Steroid doses may be further tapered on an individualized basis depending on status of patient and function of graft. Adjustments in dosage of prednisone must be made according to the clinical situation.
<P>PROBLEM TO BE SOLVED: To provide a method for improving biomembrane permeability by a simple method, especially skin permeability, namely percutaneous absorption and to provide a composition.  <P>SOLUTION: The biomembrane-permeable composition comprises an aqueous mixture containing a membrane-permeable carrier, an acidic compound and a basic compound having biological activity. The membrane-permeable carrier has a peptide composed of 6-25 amino acid residues, at least 50% of the total amino acid residues of the peptide is composed of amino acid residues having guanidino groups and/or amidino groups at the side chains. The peptide contains at least six continuous amino acid residues having guanidino groups and/or amidino groups at the side chains. The membrane-permeable carrier is preferably a peptide containing 6-15 continuous arginine residues. Ascorbic acid or citric acid is used as the acidic compound.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE: Upper urinary tract stones are a common condition in urology clinics. Percutaneous nephrolithotomy (PCNL) is an effective procedure frequently used for the treatment of stones larger than 2 cm. MAP scoring is used to predict oncological outcomes and intraoperative complications after partial nephrectomy by using the thickness and adhesion of perinephric adipose tissue. We examined the relationship between MAP score and clinical and demographic findings of the patients, especially postoperative Hgb drop and postoperative complications.
MATERIAL-METHOD: Patients were divided into 2 groups: Those with MAP score < 3 and ≥ 3. The impact of the MAP score on the demographic, clinical, and surgical parameters of the groups was assessed and analyzed. The relationship between MAP score and complications based on Clavien Dindo classification was also examined. The study investigated factors affecting the development of complications, the amount of bleeding, and the influence of MAP scores on these outcomes.
RESULTS: The Hgb drop was 2.56 ± 1.00 in the group with a MAP score ≥ 3 which was statistically significantly higher than the group with a MAP score < 3 (1.43 ± 1.21) (p < 0.001). The stone-free rate was 81.7% in the group with a MAP score < 3, which was statistically significantly higher than the group with a MAP score ≥ 3 (59.6%) (p = 0.012).
CONCLUSION: As the MAP score of patients scheduled for standard PNL operation increased, there was a corresponding rise in Hgb drop, a decline in stone-free rates and an uptick in postoperative urinary complications of postoperative urinary infections.
Sacroiliac joint dysfunction is a source of low back pain that causes significant pain and disability. Injection of the sacroiliac joint with a local anesthetic/corticosteroid mixture has shown efficacy in treating this condition, when conservative therapy fails. The use of fluoroscopic guidance and anatomic landmarks are traditional methods for performing this injection; however, ultrasound imaging has recently been utilized for performing this procedure. Although studies exist that describe and validate the ultrasound technique, no studies exist that compare the techniques with respect to short-term and long-term outcomes. In this study, the primary objective is to determine if a difference exists between a fluoroscopic-guided technique and ultrasound-guided technique with respect to pain and function. A secondary objective is to compare the two techniques with respect to procedural characteristics.
PURPOSE: Provided are thermochroism ink, nail lacquer and their application method. The invention is about the solvent base containing theromochroism pigments with pH 6.6-7.5 and acid value of more than 100. This pigments are micro-encapsulated and contain the reversible thermally changeable color materials from one color to another color. CONSTITUTION: The composition of the thermochroism ink is prepared by making a slurry containing thermochroism pigments with 80-90% solid content, mixing above slurry in powder form in a microwave bath with mixed base including trace of ketone, secondary alcohol, aldehyde, amine and aromatic compound as only solvents, and adding at least one component selected from mixed vanish, polyester resin vehicle and colloid dispersing resin. The nail lacquer is similarly prepared by mixing the micro-encapsulated thermochroism color materials, with 5-50 micrometer of capsule size, changing one color to another by temp. change with mixed base having trace solvents chosen only from ketone, sec-alcohol, aldehyde, amine and aromatic compound. The application method of the above ink comprise; washing the surface of the printing machine where the ink is to contact, providing distilled water jet solution to the thermochroism ink, putting the ink into the printing machine and printing image to the substrate with the ink and water jet.
Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
PURPOSE:To obtain a hair nourishing agent having excellent effects on hair growth, hair nourishment, prevention of hair removal, prevention of dandruff, etc. CONSTITUTION:The hair nourishing agent comprises (A) an extract of Aconitum chinense Sieb. and (B) chlormadinone acetate (chemical name: 6-chloro-17- hydroxypregn-4,6-diene-3,20-dione-acetate) used as a therapeutic agent for prostatic hypertrophy or cancer or spinolactone (chemical name: 17-hydroxy-7- mercapto-3-oxo-17alpha-pregn-4-ene-21-carboxylic acid gamma-lactone used as a diuretic in a content ratio of 0.0001-20.0wt.% component A (calculated as dried substance) and 0.0001-3.0wt.% component B. In extracting Aconitum chinense Sieb., 100-5,000ml solvent is extracting Aconitum chinense Sieb., 100-5,000ml solvent is used based on 100g Aconitum chinense Sieb. and the extraction is carried out preferably at room temperature to the boiling point of the solvent under normal pressure. The hair nourishing agent is properly mixed with a coloring matter, a perfume, a germicide, an antiseptic, a keratin solubilizer, an antiinflammatory agent, a hair nourishing agent, vitamins, an antioxidant, a refreshing agent and other galenical extract drugs, etc.
The invention provides a composition for treating and preventing Alzheimer's diseases, which consists of monacolins, an anti-inflammatory agent and an antioxidant according to a specific weight ratio, wherein the monacolins, the anti-inflammatory agent and the antioxidant are extracted from fermented red yeast rice, and the fermented red yeast rice is prepared from Oryzasati VaL. (Japonica) serving as a raw material by an appropriate controlled fermentation process. The invention further provides a preparation method of the composition for treating and preventing Alzheimer's diseases. The Oryzasati VaL. can be fermented into the fermented red yeast rice by the appropriate controlled fermentation process, and the fermented red yeast rice is ground and then used as the composition for treating and preventing Alzheimer's diseases. According to the composition for treating and preventing Alzheimer's diseases and the preparation method thereof, the composition consisting of the monacolins, the anti-inflammatory agent and the antioxidant has the effect of treating and preventing Alzheimer's diseases.
Non-hospitalized COVID-19 patients who have positive PCR results and show mild to moderate clinical manifestations and symptoms (20-30 patients) will receive a 50% standardized olive leaf capsule 750 mg (700 mg oleuropein/day; the active principle in olive leaf) two times daily for a period of ten days alongside with the Egyptian protocol medications. All the active comparator participants should be adults, with no chronic diseases (except hypertension and diabetes), non addict or alcoholics.
The participant will be treated with pelvic floor physical therapy once a week for 8 weeks. Physical therapy involves standard approach of manual therapy including trigger point release, soft tissue mobilization, stretching, biofeedback, breathing techniques, relaxation yoga, and therapeutic exercises.
This clinical trial will be conducted at our Division of Vascular Surgery and Endovascular Surgery at the University Hospital of Salzburg. Patients will be randomized into one of the two treatment options (plain old ballon angioplasty versus sirolimus coated balloon angioplasty). The recruitment phase is calculated for two years with a planned follow-up of 2 years. Follow-up data will be collected to answer the endpoints and will include all available follow-ups to monitor the shunt up to 2 years after the procedure. Typically, follow-up visits will be conducted at 6 weeks, 3 months, 6 months, 12 months, and 24 months after the procedure.

The shunts are checked for functionality as part of the dialysis required three times a week and presented to our department beforehand in need. This saves chronically ill patients the additional waiting time in hospital outpatient departments.
INTRODUCTION: Diverticulitis can be complicated by fistulas between the colon and neighboring structures, which predispose to significant morbidity and mortality. Fistulas involving the female urogenital tract often present with urogynecologic symptoms, such as vaginal discharge or recurrent urinary tract infections. While colo-vaginal fistulas, a more common variant, often present with vaginal flatulence, colo-salpingeal fistulas are exceedingly rare and have not been reported with this symptomatology. We describe a case of colo-saplingeal fistula presenting with vaginal flatulence, requiring multidisciplinary collaboration for diagnosis and management.
CASE: A 63-year-old woman presented with vaginal flatulence in the setting of persistent diverticulitis. Computed tomography (CT) scan revealed sigmoid diverticulitis, a submucosal abscess abutting the uterus, and air within the endometrial cavity, raising suspicion for a colo-uterine fistula. Following transient symptomatic relief with medical management and antibiotics, recurrence of symptoms prompted surgical intervention. Laparoscopic exploration allowed diagnosis of the colo-salpingeal fistula. Sigmoid colectomy and left salpingo-oophorectomy were performed with a minimally invasive surgical approach, resulting in an uncomplicated recovery with remission of symptoms.
DISCUSSION: This rare case highlights novel gynecologic symptoms for a colo-salpingeal fistula, contrasted with reported presentations through a comprehensive literature review. This case underscores the importance of recognizing gynecologic symptoms related to diverticular disease, which may be subtle, but provide important considerations for prognosis and treatment. A multidisciplinary approach to care from diagnosis through surgery allowed for successful recognition and minimally invasive treatment of this anomalous condition before further complications could arise. Ultimately, surgical approaches to diverticulitis-associated gynecologic fistulas should be individualized.
FIELD: cosmetology. SUBSTANCE: liquid composition comprises surfactant, water-insoluble active agent, water and long-chain alcohol or derivative thereof intended to stabilize liquid composition so as to make it storageable at higher temperature such as temperatures liable to occur during storage in countries with warm climate. Presence of alcohol or its derivatives also contributes to enhance affinity of fiber- and leather-processing agents to fibers and leather. Proposed composition can be also used as cosmetic preparations producing favorable effect on human hair and skin, such as shampoos; aromatized shampoos; hair-conditioning, hair-styling compositions; anti-dandruff preparations; skin-softening, antistatic compositions; detergents; skin cleaners; skin lotions and preparations for protection against sun. EFFECT: higher quality. 19 cl, 6 tbl
Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
Participants will take Atomoxetine (80mg) and Oxybutynin (5mg) before bedtime for 3 nights. Half doses will be given on the first night.
A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
The global surge in refractive surgeries, particularly among myopic individuals, has elicited concerns regarding potential inaccuracies in the measurement of intraocular pressure (IOP) post surgery, primarily associated with central corneal thinning. The incidence of elevated IOP after intraocular refractive surgeries is higher than expected and is multifactorial. Myopic eyes have a higher susceptibility to both primary and secondary glaucoma. Consequently, meticulous preoperative screening for glaucoma is imperative, coupled with systematic postoperative follow-up and evaluation. This comprehensive review analyses the etiology, mechanisms, and therapeutic strategies for managing elevated IOP following refractive surgery. We propose an algorithm to summarize the causative factors of elevated IOP and formulate effective interventions in these instances.